Drugs / Bemnifosbuvir/Ruzasvir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07314346 | Jan 2025 → Aug 2026 overdue | — | Atea Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemnifosbuvir/Ruzasvir | “Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone” NCT07314346 ↗ |
| Known as | BEM/RZR | “Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone” NCT07314346 ↗ |
| Route | Oral | “Multiple Oral Doses of BEM/RZR FDC” NCT07314346 ↗ |